Intensity Therapeutics Bolsters Financial Position with $6.6 Million from At-The-Market Stock Sales

Intensity Therapeutics, Inc. (Nasdaq: INTS), a biotechnology firm at the forefront of developing intratumoral cancer therapies, reported a significant financial milestone in July 2025. The company secured $6.6 million in gross proceeds, netting $6.3 million, through the sale of 19,868,658 shares of its common stock via an At-the-Market (ATM) offering. This strategic move, executed at an average price of $0.3323 per share, has bolstered the company's balance sheet, providing essential funding to propel its clinical trials into the latter half of 2026.

Lewis H. Bender, President and CEO of Intensity Therapeutics, highlighted the advantages of the ATM sales, noting the favorable pricing and lower capital-raising costs compared to previous offerings. The company's approach to capitalizing on market conditions underscores its commitment to advancing its proprietary cancer therapies, including INT230-6, its lead investigational product designed for direct intratumoral injection.

INT230-6 represents a breakthrough in cancer treatment, leveraging Intensity's DfuseRx℠ technology to deliver potent anti-cancer agents directly into tumors. This method not only aims to kill tumors locally but also engages the immune system to recognize and combat cancer systemically, without the immunosuppressive effects commonly associated with chemotherapy. The ongoing clinical trials, including Phase 3 studies in soft tissue sarcoma and Phase 2 studies in triple-negative breast cancer, are pivotal in evaluating the efficacy and safety of INT230-6.

The successful ATM offering and the progress in clinical trials underscore Intensity Therapeutics' potential to revolutionize cancer treatment. By focusing on innovative intratumoral therapies, the company is paving the way for new treatment paradigms that could transform deadly cancers into manageable conditions. For further details on Intensity Therapeutics and its groundbreaking research, visit https://www.intensitytherapeutics.com.